PředmětyPředměty(verze: 953)
Předmět, akademický rok 2023/2024
   Přihlásit přes CAS
Pharmacology II - DA0108363
Anglický název: Pharmacology II
Zajišťuje: Ústav farmakologie (13-311)
Fakulta: 2. lékařská fakulta
Platnost: od 2023 do 2023
Semestr: zimní
Body: 4
E-Kredity: 4
Způsob provedení zkoušky: zimní s.:
Rozsah, examinace: zimní s.:60/60, Z+Zk [HT]
Rozsah za akademický rok: 1 [týdny]
Počet míst: neomezen / neomezen (neurčen)
Minimální obsazenost: neomezen
4EU+: ne
Virtuální mobilita / počet míst pro virtuální mobilitu: ne
Stav předmětu: vyučován
Jazyk výuky: angličtina
Způsob výuky: prezenční
Způsob výuky: prezenční
Vysvětlení: 1 týden semináře = 30 hodin, 60 hodin přednáška, 30 hodin praktické cvičení
Garant: doc. RNDr. Eva Kmoníčková, CSc.
Kategorizace předmětu: Farmacie > Předměty širšího základu
Prerekvizity : DA0105341, DA0105439, DA0107363
Je prerekvizitou pro: DA0110369, DA0110308, DA0110317, DA0110016, DA0110068, DA0110036, DA0110010, DA0110315, DA0110002, DA0110313
Anotace - angličtina
Teaching in the 4th year continues in the form of lectures and 2 blocks (seminars) on pharmacology I. In special pharmacology, in addition to the basic characteristics of individual drug groups, emphasis is placed on the treatment of individual nosological units and the rational use of drugs in compliance with generally valid legal and professional regulations (e.g. recommended treatment procedures of professional societies). An integral part of the teaching of pharmacology is the knowledge and skill of prescribing drugs, both mass-produced medicinal products and individually prepared ones.
Poslední úprava: Mokoš Miroslav, Ing. (27.09.2022)
Cíl předmětu - angličtina

The main objective of the study of pharmacology is to acquire knowledge that would help to increase the efficacy, safety and rationality of drug use in clinical practice. The ultimate goal is the application of this knowledge in the prevention, diagnosis and treatment of human diseases.

Poslední úprava: Kovář Jan (08.07.2022)
Podmínky zakončení předmětu - angličtina

Lectures: are recommended, ppt. lecture presentations and useful questions resulting from the lectures are available at MOOODLE.

Seminars are in blocks: one absence for serious reasons is possible within one block (see Dean's Action 4/2022). An absence of the type "I'm going to help with the teaching of another subject") is not possible. If distance learning is necessary, both blocks will be available on MOODLE. You must bring a mobile phone/tablet (internet connection) to the seminars. Some classes will take place in computer room C 205 event. B 114 ( will be announced in due course).

The schedule of lectures and seminars is in MOODLE and on the bulletin board in front of room C 209 in Plzeňská campus).

Conditions for granting credit:

Credit will be awarded on the basis of attendance, active participation during individual days, which will include continuous testing (e.g. in the form of sw Socrative), final test in each block + students' own presentation on the chosen topic in the 1st or 2nd block. The final test in each block will be on Friday (event on Thursday if Friday is a holiday). It will contain questions from the topics discussed in the seminars and from topics for self-study, the limit for completing the test: 70% and more. Otherwise, the student writes a correction test in the time outside the block and after teaching all the student groups of the given block.

Conditions for exam:

In addition to two credits, i.e. from summer semester and from blocks, a "big" pre-examination test in Moodle must be completed. The minimum pass rate for each test is 80%. Tests can be repeated until the desired success is achieved. All tests must be completed by the exam date, which means that it is not possible to pass the exam without writing credit tests!!!


The oral exam in pharmacology can only be taken after meeting the conditions for obtaining credit. The exam consists of a verification of knowledge of prescription (specialties and magistraliter of preparations) and 3 theoretical questions. It includes questions from general and special pharmacology and pharmacotherapy of important clinical conditions. It is not allowed to use drug information resources or any electronic devices (including mobile phones) during the exam.

Exam period: starts at the turn of February/ March and ends on the last day of June. ALL STUDENTS ARE REQUIRED TO REGISTER FOR THE 1ST TERM OF THIS PERIOD. THERE WILL BE REPAIR DATES ONLY IN SEPTEMBER!

Poslední úprava: Kmoníčková Eva, doc. RNDr., CSc. (28.09.2023)
Literatura - angličtina

Lippincott Illustrated Reviews: Pharmacology, 7th ed,, 2019, authors: Whalen Karen, Carinda Feild; Rajan Radhakrishnan; Philadelphia: Wolters Kluwer 2019. (A), (available as e-book)

++ Rang & Dale´s Pharmacology: Churchill Livingstone, 9th ed., 2019 (A) or Rang & Dale´s Pharmacology, Elsevier, 10th ed., 2024, (A), (both available as e-books)

++ Katzung, B. G.: Basic & Clinical Pharmacology: Mcgraw Hill Education & Medic, 15th ed. 2020 (A) (available as e-book)

++ Lüllmann, H., Klaus M., Lutz. H: Color Atlas of Pharmacology; Thieme, 5th ed., 2018 (available as e-book)

++ Neal, M. J.: Medical Pharmacology at a Glance, 9th Edition, Wiley- Blackwell , 2020 (A),

(available as e-book)

Dale's Pharmacology Condensed: With STUDENT CONSULT Online Access, Elsevier, 2021

A…outside the library

B…only to the study room

D…will be published during the school year

E…personally at the clinic

+ obligatory

++ recommended

Lectures: https://dl1.cuni.cz/course/view.php?id=6110

Pharmacology quizes: https://dl1.cuni.cz/course/view.php?id=5669

Poslední úprava: Kmoníčková Eva, doc. RNDr., CSc. (13.09.2023)
Požadavky ke zkoušce - angličtina


1. Pharmaceutical, medicinal product, batch, (illegal) drugs, life cycle of drugs, dispensing of drugs in a pharmacy.

information about drugs.

3. Names of pharmaceuticals/drugs, generic drugs, brand (name) drugs, prescription-only drugs (POM), over-the-country drugs (OTC), drug bioequivalence.

4. Development of drugs and clinical trials, clinical trial phases, approval requirements

5. Drug toxicity, toxicity test, drug dose, teratogenic, mutagenic and carcinogenic effects of drugs. Examples.

6. Pharmacovigilance: importance, basic principles, undesirable effects of drugs, drug side effect reporting.

7. Marketing authorization of a drug, original and copy (proprietary and non-proprietary), synthetic and biological drugs, drug-related legislation and Anatomic Therapeutic Chemical (ATC) classification of drugs, drug promotion and marketing.

8. Proprietary medicinal products, individually prepared medicinal product, patient information leaflet, SPC.

9. Information provided about drugs, medical product price regulation, drug reimbursement from public health insurance system.

10. Drug regulatory agencies, basic legislative standards for handling of drugs.

11. Addictive substances, principles of prescribing intoxication and psychotropic substances.

12. Medical prescription, technique of prescribing proprietary medicinal products.

13. Principles and technique of prescribing individually prepared medicinal products, (magistral preparations).

14. General principles governing drug pharmacokinetics: drug movement within the body, microcirculation, filtration, biological barriers.

15. Factors affecting drug passage across biological membranes, water or fat drug solubility, ionization status and pH of the environment.

16. Transport of the molecule of a pharmaceutical across the cell membrane, division of transport processes by energy requirements, passive transport, active transport, facilitated diffusion, membrane transport proteins (transporters), channel proteins.

17. Effect of physical-chemical properties of pharmaceuticals on protein binding and their distribution within the body. Binding affinity.

18. Pharmacokinetics, pharmacokinetic parameters.

19. Pharmacokinetic processes, zero and first order kinetics.

20. Drug absorption, factors affecting absorption, interactions at the level of absorption, bioavailability, drug concentration, amount of drug in the body.

21. Binding of pharmaceuticals to (body) proteins, drug distribution, volume of distribution, their importance for clinical practice, selective accumulation of drugs.

22. Distribution of drugs in the body (volume of distribution, its importance for drug dosing), loading dose, loading dose calculation.

23. Drug metabolism, Phase I and II biotransformation reactions.

24. Biotransformation reactions of drugs and their importance for effect and elimination of pharmaceuticals from the body (types of biotransformation reactions, enzyme induction and inhibition).

25. Pro-drugs, their clinical relevance, examples, factors affecting drug metabolism.

26. Elimination of drugs in case of failure of elimination organs - possibility of dosage adjustment

27. Pharmaco-genetics and its use in clinical practice (importance, use in practice, examples).

28. Drug elimination (clearance), renal, hepatobiliary elimination, organs of elimination.

29. Rate of drug elimination from the body, renal and hepatic clearance (elimination constant, elimination half-life).

30. Biological half-life, steady state, their relevance for clinical practice.

31. Routes of drug administration (relationship between technique of administration and rate of onset plus duration of effect of the drug, relationship to substance pharmacokinetics); dosage forms.

32. Importance of pharmacokinetics for optimizing drug dosing (relationship between dose, plasma concentration and drug action). Therapeutic drug monitoring (examples).

33. Pharmacokinetic compartment models, one-compartment, multi-compartment system, temporal course of drug levels in the body.

34. Pharmacokinetics; basic parameters and formulas for the calculation of pharmacokinetic parameters, importance of individual parameters.

35. Mode of action of drugs at the molecular level; target structures for drug action, drugs with receptor-independent action (examples).

36. Classification of receptors and their subtypes, main types of membrane receptors, G protein.

37. Basic quantitative aspects of pharmacon-receptor interaction (affinity, intrinsic activity, relevance for drug dosing and effect).

38. Intrinsic activity and affinity of xenobiotics, competitive and non-competitive antagonism and partial agonism (depict graphically the course of characterization curves).

39. Receptor desensitization and hypersensitization (mechanisms, examples). Receptor disease.

40. Major sites of drug action (receptor, ion channels, enzymes, and other). - examples

41. Dose-dependence (types of doses, dose-effect relationship, plasma level-effect relationship, therapeutic range).

42. Width of the therapeutic window, therapeutic index; individual variability in patients´ drug sensitivity/tolerance (causes).

43. Changes in the effect of drug on multiple administration (tachyphylaxis, tolerance, induction, inhibition, accumulation, drug dependence).

44. Drug-drug interaction (types of interaction and examples thereof).

45. Therapeutic drug monitoring (TDM), importance, use in practice, examples.

46. Specific features of pharmacotherapy in older persons. Changes in pharmacodynamics effects and pharmacokinetic properties of drugs (examples).

47. Pharmacotherapy and drug dosing in children.

48. Pharmacotherapy in pregnancy and breastfeeding. Main classes of drugs that can be used to treat hypertension, thrombotic states, diabetes, bronchial asthma, and infectious diseases in pregnancy.

49. Pharmacotherapy in old age.

50. Pharmaco-economics. Pharmaco-economic analyses.

51. Drug intoxication; principles of its management, management of the patient, antidotes.

52. Rational pharmacotherapy, pharmacotherapy-associated risks and polypharmacy.

53. Undesirable (adverse) effects of drugs (AE), classification (dose dependence – specific examples).

54. Dysfunction of organs of elimination and drug dosing adjustment.

55. Alternative medicine and its risks. (Traditional medicine of the Far East, homeopathy, folk medicine, medicinal plants.)




1. Antiulcer agents, antacids, gastroprotective agents, H2 blockers (H2 receptor antagonists), proton pump inhibitors

2. Laxatives: contact laxatives, stool softeners, osmotic laxatives, osmotic saline laxatives.

3. Drugs increasing GI motility (promotility drugs), prokinetic drugs: serotonin receptor (5-HT4) agonists, acetylcholinesterase inhibitors, dopamine D2 receptor antagonist, agents with side prokinetic effects.

4. Anti-emetics, serotonin 5-HT3 receptor antagonists, neurokinin 1 (NK1) receptor antagonists, histamine H1 receptor antagonists, neuroleptics (antipsychotic medications) with antiemetic action, glucocorticoids as anti-emetics.

5. Rehydration solution in diarrheal diseases and principles of trace elements and ion supplementation in diarrheal diseases

6. Intestinal adsorbents and antidiarrheal agents: enkephalinase inhibitors, opioid antidiarrheal agents, intestinal astringents

7. Chemotherapeutics and antibiotics used in the treatment of bowel infections.

8. Anti-obesity drugs

9. Pancreatic enzymes

10. Spasmolytics

11. Choleretics

12. Hepatoprotective agents

13. Aminosalicylates used in the treatment of inflammatory bowel disease

14. Glucocorticoids in the treatment of inflammatory bowel disease

15. Immunosuppressants used in the treatment of inflammatory bowel disease

16. Biologics used in the treatment of inflammatory bowel disease

17. Anti-hemorrhoid drugs

18. Fibrinolytic and antifibrinolytic drugs

19. Antiplatelet agents/drugs: irreversible cyclooxygenase inhibitors, adenosine diphosphate (ADP) receptor inhibitors, glycoprotein IIb/IIIa inhibitors

20. Anticoagulants: vitamin K antagonists, gatrans, xabans

21. Anticoagulants: indirect thrombin inhibitors (heparin and low-molecular-weight heparins), indirect selective factor Xa inhibitors

22. Medicines in the secondary prevention of ischemic heart disease

23. Positive inotropes

24. Nitrates and nitric oxide (NO) donors

25. Beta-blockers

26. Calcium-channel blockers

27. ACE inhibitors

28. Angiotensin (II) receptor blockers

29. Modulators of cardiac metabolism, renin inhibitors, inhibitors of natriuretic peptide degradation

30. Diuretics

31. Vasodilators centrally (imidazoline receptor agonists, presynaptic α2 adrenergic receptor agonists) and peripherally (α1-adrenergic receptor blockers) acting vasodilators

32. Vasodilators: phosphodiesterase 3 inhibitors, vasodilatory prostaglandins, serotonin 5-HT2 receptor antagonists, xanthine peripheral vasodilators, phosphodiesterase 5 inhibitors

33. Vasodilators used in the treatment of pulmonary hypertension: soluble guanylate cyclase activators, endothelin receptor antagonists, prostacyclin and prostacyclin analogues, prostacyclin receptor agonists

34. Antiarrhythmic agents

35. Lipid-lowering drugs

36. Anti-varicose drugs, vasodilators, nootropics - cognitive drugs

37. Analgesics – antipyretics

38. Analgesics – non-steroidal anti-inflammatory drugs, COX-2 inhibitors

39. Analgesics - opiates

40. Expectorants, mucolytics, antitussives

41. Antipsychotics

42. Antidepressants

42. Anxiolytics and hypnotics

44. Thyroid and anti-thyroid drugs

45. Insulins and insulin analogues

46. Oral antidiabetics and incretin mimetics

47. Secretagogues, peripheral insulin sensitizers, α-glucosidase inhibitors. Incretins, inhibitors of DPP4 and inhibitors of SGLT2

48. Hormonal contraception

49. Cytostatic drugs overview

50. General anesthetics and local anesthetics

51. Antihistamines and glucocorticoids

52. Immune system modulators, immunosuppressants, immunomodulators

53. Division of antibiotics

54. Antibiotic therapy-associated risks – undesirable (side) effects and issues related to resistance

55. Penicillin antibiotics

56. Cephalosporins

57. Carbapenems and aztreonam

58. Glycopeptide antibiotics

59. Fluoroquinolones

60. Macrolides

61. Azalides, ketolides, linezolid and other protein synthesis inhibitors

62. Aminoglycoside antibiotics

63. Anti-tuberculous drugs/anti-TB drugs

64. Tetracyclines, tigecycline, chloramphenicol

65. Sulphoamides, co-trimoxazole

66. Antiviral drugs

67. Local and systemic antifungals

68. Anti-parasitic drugs, (amoeba, trichomonas, toxoplasma, pneumocystis, worms, scabies, louse...). Anti-malarial drugs, antiseptics and disinfectants.

69. Drugs used in the treatment of bone metabolism disorders

70. Anti-parkinson drugs

71. Anti-anemic drugs (Fe, vitamins group B, hematopoietic growth factors, anabolics, glucocorticoids)

72. Infusion solutions, parenteral nutrition, transfusion preparations – division, risks

73. Centrally- and peripherally-acting muscle relaxants

74. Antiasthmatic drugs (selective 2-sympathomimetics, parasympatholytic agents – anticholinergics, glucocorticoids).

75. Theophylline and other xanthines, preventive asthma (controller) medicines (anti-inflammatory agents, immunoprophylactic agents, mast cell stabilizers, leukotriene modifiers), mucolytics, expectorants, antitussives

76. Antiepileptic drugs

77. Drugs used in obstetrics (prostaglandins, ergot alkaloids, tocolytics)

78. Drugs used in the treatment of urinary tract disorders (cholinergic drugs, anticholinergic drugs, sympatholytic drugs, 5α-reductase inhibitors, α1-blockers)

79. Female and male sex hormones

80. Minerals and trace elements

81. Vitamins

82. Biologic drugs (biologics)

83. Sympatholytic drugs, sympathomimetic drugs

84. Parasympatholytic drugs, parasympathomimetic drugs

85. Active and passive immunization, prophylactic and therapeutic vaccines

86. Ethanol – psychotropic and antimicrobial activity, mechanisms of action. Addiction treatment. Teratogenic effects.

87. Hemostatic drugs

88. Pancreatic hormones (insulin, glucagon, amylin)

89. Drugs affecting pituitary function

90. Hypothalamic hormones

91. Adenohypophyseal hormones

92. Posterior pituitary hormones

93. Hormones of the adrenals

94. Glucocorticoids

95. Mineralocorticoids

96. Glucocorticoid and mineralocorticoid hormone antagonists

97. Hormones regulating the female reproductive system

98. Drugs used in hormone replacement therapy during menopause (HRT)

99. Male sex hormones, anabolic steroids

100. Cytokines – regulatory peptides

101. Targeted therapy in oncology (monoclonal antibodies, tinibs)




1. Pharmacotherapy of dyspepsia

2. Pharmacotherapy of gastroduodenal ulcer disease, Helicobacter pylori eradication

3. Principles of pharmacotherapy of constipation

4. Pharmacotherapy of nausea and vomiting

5. Pharmacotherapy diarrheal diseases

6. Pharmacotherapy of meteorism, gallbladder and bile duct diseases

7. Pharmacotherapy of liver diseases

8. Pharmacotherapy of inflammatory bowel disease

9. Pharmacotherapy of obesity

10. Pharmacotherapy of hemorrhoids

11. Pharmacotherapy of acute myocardial infarction

12. Pharmacotherapy of chronic heart failure

13. Pharmacotherapy of acute heart failure

14. Pharmacotherapy of stroke

15. Pharmacotherapy of epilepsy

16. Pharmacotherapy of osteoporosis

17. Pharmacotherapy of thyroid diseases

18. Pharmacotherapy of asthma and chronic obstructive pulmonary disease (COPD)

19. Pharmacotherapy of diabetes

20. Pharmacotherapy of hypertension

21. Pharmacotherapy of vein thrombosis

22. Pharmacotherapy of pulmonary embolism

23. Pharmacotherapy of pain

24. Pharmacotherapy cardiac rhythm disorders

25. Pharmacotherapy of bronchopneumonia

26. Pharmacotherapy of urinary tract infections (UTI)

27. Pharmacotherapy of peripheral arterial disease

28. Pharmacotherapy of respiratory tract infections

29. Pharmacotherapy of anaemia (Fe, B vitamins, hematopoietic growth factors, anabolics and glucocorticoids in anaemia)

30. Pharmacotherapy of glaucoma

31. Pharmacotherapy of dyslipoproteinemias

32. Pharmacotherapy of depression

33. Pharmacotherapy of allergic conditions

34. Pharmacotherapy of fever

35. Pharmacotherapy of cough

36. Pharmacotherapy of migraine

37. Pharmacotherapy of gout

38. Basics of ATB therapy

39. Basics of treatment in oncology. Safety of work with cytostatics

40. Medicines used in cystic fibrosis (CF)

41. Vaccines and their types.

42. Neuropathic pain and its treatment.

43. Monoclonal antibodies - mechanisms of action and indications – examples.

44. First aid kit equipment for travel. (Medicaments)

45. Hormonal treatment modalities (in oncology)

46. Pharmacotherapy of angina pectoris

47. Principles of gene therapy and its use




1. Prescribe antibiotic for paediatric patient 6 years to treat pneumonia. What are the potential side effect?

2. Prescribe antipyretic treatment for paediatric patient 4 years to treat high fever. What type of drug presentation can we suggest in case of vomiting?

3. Prescribe strong analgesic treatment for oncology patient suffering from metastasis.

4. Prescribe diuretics for adult patient as part of hypertension treatment. What are the possible side effects? What type of other drugs would you suggest?

5. Prescribe treatment of tachycardia for 2 month. What are the possible side effects?

6. Prescribe an oral treatment of diabetes DMII for 1 month. What are the possible side effects?

7. Prescribe antihistamine treatment of for an allergic patient for 2 month. What are the possible side effects?

8. Prescribe hypnotics for elderly patient. What are the possible side effects?

9. Prescribe anti-aggregation treatment to prevent thrombosis. What are the possible side effects?

10. Prescribe analgesic treatment (antiplatelet) for a patient suffering from osteoarthritis of left knee. What are the possible side effects?

Poslední úprava: Kmoníčková Eva, doc. RNDr., CSc. (13.09.2023)
Sylabus - angličtina
The syllabus Pharmacology 2nd Medical Faculty

Lectures and Seminars

Introduction to Pharmacology

Basic terminology, types of treatment, development of new drugs, medicines act

General pharmacology


Absorption, distribution, elimination and biotransformation of drugs

Receptor theory, mechanism of drug actions

Mechanism of regulation, receptors, mediatros, agonists, antagonists

Interactions of drugs

Mutual effects of drugs, toxicity

Development of new drugs

Development of new drug, preclinical and clinical assessment, registration

Special pharmacology

Pharmacology of the autonomic nervous system

Physiology, receptors, mediators, agonists, antagonists, mechanism of action

Parasympathetic nervous system - parasympathomimetics, parasympatolytics

Sympathetic nervous system - agonists, antagonists, sympathomimetics, sympatholytics

Cardiovascular system

Antiarhytmic drugs

Cardiac Arrhytmias, drugs affecting heart output, heartrate, classification

Therapy of heart failure

Heart failure, digitalis, positive inotropic effect, cardiac hypertrophy

Beta blockers

Beta receptors, classification, Clinic use and strategies

Drugs used in blood coagulation disorders


Mechanism of action, classification

Respiratory system

Drugs for Asthma treatment, mucolytics, cough preparations


Histamin, pathofysiology, effects, H1 and H2 agonists, clinical use 1st and 2nd generation

Drugs used in GIT

Drugs and the liver, therapy of peptic ulcers, spasmolytic agents, motility stimulating agents, laxatives, therapy of diarhoe

Hypolipidemic drugs

Types of pareticles, types of disorders, statins, fibrates, nicotin acid

Drugs used in rheumatic disease and OA


Analgetics - antipyretics

Effects, mechanism of action, dosage, main groups

Analgetics - opioids

Morfin and its derivates, analgetic receptors, mechanism of action, clinical use, combinations of analgetics

General anaesthetics

Neuromuscular blocking agents, classification, mode of action


Classification and indications, mechanism of action

Penicillins, Cephalosporins, Macrolides, Tetracyclins, Aminoglycosides, Quinolones, Combination

Antiviral Drugs

Classificaton, specific use, AIDS, toxicity

Antidiabetic drugs

Classification, mechanism of action, oral antidiabetic drugs, insulins

Central nervous system Pharmacology

Mediators of CNS, classification, hypnotics and anxiolytics, drugs used in psychoses, antidepressant drugs, neuroprotective drugs


Pathophysiology, effects, indications, risks

Drug policy

Rationa, pharmacotherapy, drug reimbursement, drug utilization


General pharmacology

Prescrtiption of Drugs

Introduction to rational drug prescribing

Patient-drug concept

Prerequisites for earning credits in pharmacology, MA degree program

The Institute provides education/training of Czech and English-speaking students.

Education in Grade IV - pharmacology for Czech and English-speaking students.

Prerequisites for earning credits in pharmacology, MA degree program

Poslední úprava: Kovář Jan (08.07.2022)
Rozpis rozvrhový
Rozvrhový lístek Datum Od - Do Typ výuky Téma Učitel Soubory Poznámka

Okruhy studentů
Po 06.11.2023 8:00 - 13:00 cvičení doc. RNDr. Eva Kmoníčková, CSc.
Út 07.11.2023 8:00 - 13:00 cvičení doc. RNDr. Eva Kmoníčková, CSc.
St 08.11.2023 8:00 - 13:00 cvičení doc. RNDr. Eva Kmoníčková, CSc.
Čt 09.11.2023 8:00 - 13:00 cvičení doc. RNDr. Eva Kmoníčková, CSc.
Pá 10.11.2023 8:00 - 13:00 cvičení Classes are held on this day in classroom C205 from 8:00 a.m. to 1:00 p.m. doc. RNDr. Eva Kmoníčková, CSc.

Okruhy studentů
Po 04.03.2024 8:00 - 13:00 cvičení doc. RNDr. Eva Kmoníčková, CSc.
Út 05.03.2024 8:00 - 13:00 cvičení doc. RNDr. Eva Kmoníčková, CSc.
St 06.03.2024 8:00 - 13:00 cvičení doc. RNDr. Eva Kmoníčková, CSc.
Čt 07.03.2024 8:00 - 13:00 cvičení doc. RNDr. Eva Kmoníčková, CSc.
Pá 08.03.2024 8:00 - 13:00 cvičení Classes are held on this day in classroom C205 from 8:00 a.m. to 1:00 p.m. doc. RNDr. Eva Kmoníčková, CSc.
Univerzita Karlova | Informační systém UK